vimarsana.com
Home
Live Updates
Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401 : vimarsana.com
Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401
/PRNewswire/ -- Kairos Pharma, Ltd. ("Kairos"), a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer,...
Related Keywords
United States ,
Los Angeles ,
Tagrisso Astrazeneca ,
Neil Bhowmick ,
John Yu ,
Ramachandran Murali ,
Kairos Pharma ,
Trademark Office ,
Cedars Sinai Medical Center ,
Kairos Pharma Ltd ,
Development Dr ,
Cedars Sinai Medical ,
Chief Scientific Officer Neil Bhowmick ,
United States Patent ,
Td ,
vimarsana.com © 2020. All Rights Reserved.